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SUMMARY 
Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal 
dysplasia (XLHED), in which the development of sweat glands is irreversibly impaired 
and which can lead to life-threatening hyperthermia. We observed normal development 
of mutant mouse fetuses following intrauterine exposure to a recombinant protein that 
includes the receptor-binding domain of EDA. We administered this protein intra-
amniotically to two affected twins at gestational weeks 26 and 31, and to a single affected 
fetus at gestational week 26; infants born in week 33 (twins) and week 39 (singleton) 
could sweat normally and had not developed XLHED-related morbidity by 14-22 
months of age. 
 
During embryonic development, tissues and organs form in spatiotemporally defined 
successions of events until the organism has acquired its final shape. Many of these events, 
such as limb morphogenesis1 or the formation of sweat glands and other skin appendages,2 
can be irreversibly affected if specific signals are not provided at the appropriate time. For 
example, deficiency of ectodysplasin A, which results from loss-of-function variants of the 
gene EDA, causes X-linked hypohidrotic ectodermal dysplasia (XLHED; MIM 305100).3 
When recombinant Fc-EDA (a fusion protein made up of the constant domain of the 
immunoglobulin G1 and the receptor-binding portion of EDA) or an antibody that activates 
the EDA receptor (EDAR) were administered repeatedly into the circulation of pregnant 
EDA-deficient mice, the disease phenotype of the pups was corrected, yet dams (homozygous 
for the loss-of-function Eda allele) did not benefit from treatment.4,5 The same was true when 
Fc-EDA was delivered directly into the amniotic fluid surrounding EDA-deficient fetuses.6 In 
the second approach, a single dose was sufficient to correct the disease phenotype and 
maternal drug exposure was negligible.6 Here we present data supporting a critical role of the 
neonatal Fc receptor in drug uptake from amniotic fluid. This receptor mediates uptake of IgG 
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from mother’s milk across the gut endothelium of rodents.7 We also report the sustained 
restoration of sweating ability in three human patients with XLHED in response to prenatal 
treatment with Fc-EDA. 
 
CASE REPORTS 
 
Patients 1 and 2 
A 38-year-old pregnant woman referred to us in gestational week 22 with a family history of 
XLHED was concerned that the twins she was carrying would be affected. Her older son had 
the disease, including a complete absence of sweat pores and sweating; genetic testing 
revealed hemizygosity for the EDA mutation c.911A>G (p.Y304C). Y304 mediates 
trimerization of EDA and its replacement by cysteine abrogates secretion of the protein (Fig. 
S1). The mother was confirmed to be a heterozygous carrier of this mutation. 
Ultrasonographic examination showed a twin pregnancy (monochorionic, diamniotic) with 
two male fetuses, both lacking tooth germs (no tooth germs at all in the lower jaw and one or 
two, respectively, in the upper jaw; normally 9-10 tooth germs per jaw are seen).10 Apart from 
that, no anomalies were evident. Additional magnetic resonance imaging confirmed the 
ultrasonographic findings and supported a diagnosis of XLHED in both twins.  
 
Inability to sweat, the most severe clinical problem of XLHED patients, can lead to life-
threatening hyperthermia after birth.11-13 Knowing that human sweat glands form between 
gestational weeks 20 and 30,14 that sweat gland development was not rescued by 
administration of Fc-EDA to XLHED patients shortly after birth (NCT01775462; 
www.clinicaltrials.gov), and that delivery of Fc-EDA into the amniotic cavity prevented 
XLHED in rodents, direct intra-amniotic drug administration at the appropriate stages of 
development appeared to be a promising therapeutic approach. We hypothesized that amniotic 
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fluid would serve as a reservoir of Fc-EDA: the size of the protein would limit its diffusion 
from the amniotic cavity and allow its uptake from the fetal gut via drinking amniotic fluid.  
Compassionate use of Fc-EDA requested by the parents of the affected twins was 
taken into consideration and finally approved by the clinical ethics committee of the 
University Hospital Erlangen. Written informed consent to intra-amniotic administration of 
Fc-EDA was obtained. Treatment was to be performed by amniocentesis at week 26 of 
gestation under ultrasound guidance with the same batch of Fc-EDA used in clinical trial 
NCT01775462. The planned procedure included withdrawal of 15 ml of amniotic fluid, 
followed by injection of Fc-EDA (100 mg/kg of estimated fetal body weight) in a 15-ml 
sterile solution into the amniotic cavity of each fetus (at 26 weeks the volume of amniotic 
fluid usually exceeds 500 ml). A second administration of the drug at 31 weeks of gestation 
was considered. EDA concentrations in serum (pregnant women, treated children) and 
amniotic fluid samples were to be determined by MPI Research Inc. (Mattawan, USA).  
 
MECHANISM OF DRUG UPTAKE IN A RODENT MODEL 
Fc-EDA is a recombinant fusion protein consisting of the receptor-binding domain of EDA 
(100% conserved between mouse and human proteins) and the Fc domain of human 
immunoglobulin G1 (EDI200, Edimer Pharmaceuticals). When administered at doses of 
approximately 100 mg/kg into the amniotic fluid of male EdaY/- mice and also Eda-/- mice 
(both sexes) at embryonic day 14.5 (E14.5), Fc-EDA prevented the development of XLHED. 
In contrast, administration of a control protein made up of the same domain of EDA but fused 
to the collagen-like domain of adiponectin did not prevent XLHED, except for two cases (in 1 
of 3 pregnancies), which could be explained by accidental introduction of the fusion protein 
into the fetal bloodstream through damage to the fetus or a peripheral yolk sac vessel with the 
injection needle (Table 1, Table S1). Furthermore, EDA-deficient fetuses that were also 
devoid of the neonatal Fc receptor were not corrected by Fc-EDA at E13.5, while all fetuses 
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expressing the neonatal Fc receptor in the same litter were corrected: they developed into 
mice that did not exhibit the disease phenotype (Table 1). The same was true for treatment at 
E12.5, except that structures (for example, guard hair) forming close to the time of injection 
were rescued more efficiently than those (such as tail hair and sweat ducts) forming at later 
stages of development (Table 1, Fig. S2). 
Because Fc-EDA rescued normal development only in the presence of intact neonatal 
Fc receptor, the therapeutic route of Fc-EDA is systemic rather than through a direct effect on 
the skin and oral epithelia. Moreover, the milk of dams who received an intraperitoneal 
injection of agonist anti-EDAR antibody (mAbEDAR1) at days 1, 2 or 3 of lactation tested 
positive for the antibody (Fig. S3). Normal development of EDA-deficient pups fed on this 
milk occurred only if they expressed the neonatal Fc receptor, indicative of neonatal Fc 
receptor-mediated uptake of this antibody in the gut (Table 1).8 Bypassing the need for 
transport mediated by the neonatal Fc receptor through direct intraperitoneal administration of 
mAbEDAR1 to newborn pups rescued normal development: the efficacy of rescue was the 
same, regardless of whether the neonatal Fc receptor was expressed (Fig. S4). In contrast, 
intraperitoneal delivery of Fc-EDA to EDA-deficient animals had much stronger effects on 
neonatal Fc receptor-positive pups than on pups devoid of it (Fig. S4). This is consistent with 
the dramatic difference in serum half-life of Fc-EDA after intravenous injection in adult mice 
with a single wild-type allele of the neonatal Fc receptor (48 hours) and in adult mice 
completely deficient of this receptor (22 minutes).  
The serum half-life of mAbEDAR1 was comparatively longer: 10 days in adult mice 
with a single wild-type allele of the neonatal Fc receptor and one day in null mice. Possibly 
the surprising efficacy of mAbEDAR1 in the absence of neonatal Fc receptor can be 
explained by the fact that exposure to EDAR agonists (delivered via intraperitoneal injection) 
for only 4 hours is sufficient to permanently correct the tail hair phenotype in newborn EDA-
 6 
deficient mice9 and because mAbEDAR1, once bound to EDAR, dissociates from it very 
slowly.5  
We concluded from these experiments that Fc-EDA provided in amniotic fluid must 
first enter the organism in a manner dependent on the neonatal Fc receptor, presumably via 
the gut, before it can act on developing EDA-dependent structures. Increased serum half-life 
of Fc-EDA in the presence of the neonatal Fc receptor further enhances treatment efficacy. 
 
PRECLINICAL TESTING IN PRIMATES 
Prior to the decision on compassionate use of Fc-EDA in human fetuses, toxicity studies had 
been conducted in cynomolgus monkeys (twice weekly intravenous infusion of Fc-EDA over 
three weeks followed by a 15-day recovery period). We did not observe signs of toxicity, 
including at the highest dose (100 mg/kg body weight). Another study in pregnant monkeys 
showed that transplacental passage of Fc-EDA after intravenous administration to the mother 
occurred in primates only at very low levels (<1% of concurrent maternal serum 
concentrations) during the equivalent of human third trimester (Table S2), suggesting that 
drug delivery to primate fetuses via the maternal circulation may not be an adequate method. 
 
CASE REPORTS (continued)  
 
Patients 1 and 2 
In February 2016, at week 26 of gestation, the affected twins were treated in utero. An 
amniocentesis of both amniotic cavities was performed to obtain amniotic fluid for genetic 
testing and to inject Fc-EDA at a dose of 100 mg/kg estimated fetal body weight. In the hours 
after administration and the following day no Fc-EDA was detectable in the circulation of the 
pregnant woman. Subsequent fetal development was uncomplicated. Genetic testing 
confirmed hemizygosity of both twins for the EDA Y304C mutation. At week 31, 39 days 
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after the first Fc-EDA administration, we injected a second dose of Fc-EDA (100 mg/kg 
estimated fetal body weight). Assays of Fc-EDA in the amniotic fluid withdrawn prior to the 
second injection gave a null result.  
Due to premature labor the treated twins were born prematurely by caesarian section at 
gestational week 32 0/7 with birth weights of 1705 and 1615 grams and Apgar scores of 8/9/9 
and 9/10/10, respectively. Although clinical assessment after birth did not reveal signs of 
infection, both neonates received antibiotics for 5 days. The neonatal course was 
unremarkable. In cord blood samples (one from each twin), Fc-EDA was still detectable 7 
days after administration at concentrations of 62.4 and 932 ng/mL, suggesting that it had been 
taken up continuously from amniotic fluid into the fetal blood. The treated infants showed a 
normal sweat-duct density15 on the soles of the feet (Fig. 1a, c) and normal pilocarpine-
induced sweating (Fig. 1b, d). Various body parts were repeatedly observed to be moist. Both 
treated boys produced amounts of sweat comparable with those of healthy control infants, 
upon stimulation with pilocarpine (Fig. 1e) or unstimulated (Fig. S6a), while their untreated 
older brother did not sweat at all. They neither experienced hyperthermic episodes during 
their first two summers nor respiratory-related hospitalizations. They also produced normal 
amounts of saliva (Fig. S6b). Transillumination revealed 3-5 and 6-7 Meibomian gland ducts 
per lower eyelid of twin 1 and twin 2, respectively, but only a single gland duct in their 
untreated brother. No obvious drug effect on hypotrichosis was observed. Postnatal MRI and 
X-ray imaging showed the presence of 10 and 8 tooth germs in the twins, respectively (Fig. 
2), compared with 3 teeth and one additional tooth germ in their untreated brother.  
 
Patient 3 
Another pregnant woman who had a son with XLHED was referred to us at week 19 of 
gestation. Ultrasonography of her male fetus showed an obvious lack of tooth germs. The 
parents requested compassionate use of Fc-EDA. This case was also considered and approved 
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by the clinical ethics committee of the University Hospital Erlangen, and written informed 
consent to prenatal treatment was obtained. Limited supply of Fc-EDA mandated a single 
dosing, which was administered at gestational week 26 into the amniotic cavity. Again no Fc-
EDA could be detected in the maternal circulation within 24 hours after drug administration. 
Genetic testing of fetal cells confirmed hemizygosity for the EDA mutation c.924+1dupG 
(p.V309GfsX8). The subsequent pregnancy and delivery were uncomplicated. The treated 
boy was born in gestational week 39 (Apgar score 10/10/10, birth weight of 3460 grams) and 
showed 1,778 and 1,822 sweat pores/cm2, respectively, on the soles of his feet, slightly fewer 
than healthy controls (Fig. 1c). At the age of 4 months he developed moderate urticaria 
pigmentosa. 
Pilocarpine-induced sweat production at 6 months of age was lower than in the treated 
twins (Fig. 1d), suggesting a slower maturation of sweat gland function.16 . In contrast to 
untreated male XLHED patients who have no more than three Meibomian glands per eyelid,17 
this treated boy showed a near-normal number of Meibomian glands (15 and 11 gland ducts 
per lower eyelid).17 In the oral cavity X-ray imaging revealed the presence of 9 tooth germs; 
his older brother had only two tooth buds  
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DISCUSSION 
 
Prenatal treatment with Fc-EDA restored sustained sweating ability in human patients with 
EDA mutations that abrogate perspiration. As yet the treated children, who are now 14 to 22 
months old, have not been reported to have experienced any hyperthermic episodes nor have 
they had respiratory-related hospitalizations. Premature labor and preterm birth were severe 
adverse events. We note that most twins are born preterm and 20% are delivered before 34 
weeks of gestation in the absence of prenatal procedures.18 The other adverse events of both 
women and their children were moderate or mild (Table S3). Signs of effects on tooth 
development and salivary and Meibomian glands have been observed in the treated infants, in 
comparison with the phenotypes of their untreated affected siblings. We do not know whether 
the therapeutic effects are permanent. We have, however, observed permanent effects in 
mouse and dog models.4-6,19,20  
 
Although the rate of amniocentesis-related miscarriage is only 0.11%,21 Fc-EDA was not 
delivered before week 26 of gestation. We reasoned that, if inadvertent rupture of membranes 
occurred at that time, it would probably be possible to prolong the pregnancy for several days 
or even weeks.22 In our opinion, the prospects of higher efficacy that could be obtained 
through earlier treatment do not outweigh even a very low risk quoad vitam. Nevertheless, 
any pre-term birth caused by the procedure would be associated with risks to baby and mother 
(increased neonatal morbidity and mortality, and maternal infection).     
                                                                                                                                                                                                                                                                                                                                                                                                                                                              
In summary, we identified a mechanism of drug uptake into fetuses resulting in effective 
treatment of a genetic disability, albeit in a very small sample (two pregnancies) and with 
limited follow-up of the live-born infants. Combined with the ability to identify affected 
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individuals by non-invasive sonographic prenatal screening,23 the approach we describe here 
represents a new means of protein replacement therapy to correct XLHED.  
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FIGURE LEGENDS 
 
Figure 1. Normalization of sweat gland development in XLHED patients treated in 
utero. 
a, Absence of sweat pores (brighter circular spots in the middle of dermal ridges) at the foot 
soles of an untreated 3-year-old boy with XLHED (left) and sweat pore densities of one of his 
treated newborn siblings (middle) and an age-matched male control (right). b, Pilocarpine-
induced sweat production of the untreated affected brother (left), a sibling treated in utero 
(middle) and an age-matched male control (right). c, In all three boys with EDA mutations 
Y304C or V309GfsX8 who had received prenatal Fc-EDA treatment (closed triangles), but 
not in untreated male infants with the same mutations (open triangles), large numbers of 
sweat pores were detected. Sweat pore density was comparable to that of healthy male infants 
(closed circles). d, In the two cases of repeated prenatal treatment (upper closed triangles), 
induced sweat production was normal at the age of 6 months and e, was shown to remain in 
the normal range until the end of the observation period. The open triangle here indicates the 
untreated older brother.  
 
Figure 2. Tooth germs of one of the patients treated in utero. 
a-c, MRI pictures showing the tooth buds of the left maxillary central incisor (a), the two 
maxillary lateral incisors (b) and both the maxillary and the mandibular central molars (c), all 
indicated by arrows. d, Dental radiography of the left maxillary region. Tooth germs of the 
upper left incisors and the upper left central molar as well as the mandibular central molar 
(arrowed) can be recognized as alveolar structures containing calcified tooth components. 
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METHODS 
 
 
Animal models  
Homozygous Tabby mice derived from white-bellied agouti B6CBAa Aw-J/A-EdaTa/J mice 
(000314; Jackson Laboratory), in some cases crossed with B6.129-Fcgrttm1Dcr/DcrJ mice 
(003982; Jackson Laboratory), were housed in individually ventilated cages under standard 
conditions with a light/dark cycle of 12 hours and free access to standard chow and tap water. 
Tabby/Tabby Fcgrt-/- females were crossed with Tabby/Y Fcgrt-/- or Tabby/Y Fcgrt+/- males, all 
selected for agouti coat color. Drug administration to the animals was performed as detailed 
below. All experimental procedures were conducted in accordance with the German regulations 
and legal requirements or according to the guidelines and under the authorization of the Swiss 
Federal Food Safety and Veterinary Office.  
Toxicity studies on 26 cynomolgus monkeys were conducted by MPI Research Inc. (Mattawan, 
USA) in accordance with the United States Food and Drug Administration (FDA) Good 
Laboratory Practice regulations. The experimental procedures are described below.  
 
Recombinant proteins, cell lines and antibodies  
Fc-EDA, a recombinant fusion protein consisting of the receptor-binding domain of EDA (aa 
238-391) and the Fc domain of human immunoglobulin G1, was provided as a sterile drug 
product (EDI200, produced according to Good Manufacturing Practice regulations) with a 
concentration of 5 mg/mL in 20 mM sodium phosphate, 300 mM sodium chloride, pH 7.2, and 
0.02% Polysorbate 20 (w/v) by Edimer Pharmaceuticals, Inc. (Cambridge, USA) and stored 
frozen at -70°C until further use. 
Flag-ACRP-EDA produced by transient transfection of HEK 293T cells was purified on anti-
Flag M2-agarose beads (Sigma) as described previously.1 Endotoxin levels were below 
Prenatal Correction of XLHED          Schneider et al.      Suppl. Page  
 
 
3 
1 unit/µg. The recombinant fusion protein hEDAR-mFc containing the extracellular domain of 
human EDAR (aa 1-183) and the Fc part of mouse IgG1 was constructed according to standard 
molecular biology procedures, produced in CHO cells and affinity-purified on immobilized 
mAbEDAR1. Anti-EDAR agonist antibody number 1 (mAbEDAR1) and hEDAR-hFc were 
generated as described.2 Anti-EDA monoclonal antibody Renzo-2 is commercially available 
(Enzo Life Sciences). 
Plasmids coding for Flag-EDA (wild-type and Y304C) were transiently transfected in 293T cells 
that were then washed and cultured for 6 days in serum-free OptiMEM medium. Cells and 
supernatants were harvested and analyzed by SDS-PAGE and Western blot with anti-EDA 
antibody Renzo-2 essentially as described.3 Sequences of proteins used are detailed in Table S2. 
 
Genotyping 
Murine genomic DNA from ear biopsies was analyzed by PCR with the following 
oligonucleotides: wild-type forward 5’-GGGATGCCACTGCCCTG-3’; mutant forward 5’-
GGAATTCCCAGTGAAGGGC; common reverse 5’-
CGAGCCTGAGATTGTCAAGTGTATT-3’ (378 bp for mutant Fcgrt allele and 248 bp for 
wild-type allele) using a 30-cycle 94°C (7 s) / 63°C (20 s) / 72°C (20 s) program. 
 
Experimental procedures on animals  
Intra-amniotic administration of ACRP-EDA or Fc-EDA to mice at different time points of 
gestation was performed as described previously.4 In some cases, Fc-EDA or mAbEDAR1 were 
injected intraperitoneally at doses of 10 mg/kg into dams within 24 hours after delivery and on 
the two days thereafter (at P1, P2 and P3). Fc-EDA, ACRP-EDA or mAbEDAR1 were also 
administered intraperitoneally to newborn pups on the day of birth at the doses indicated. The 
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treated mice were investigated postnatally for various morphological features (tail and coat hair, 
presence of sweat ducts at the foot pads, shape of the molars). Starch-iodine sweat tests were 
performed as described previously.4 For half-life determination, 200 µg of Fc-EDA or 
mAbEDAR1 were injected into the tail veins of adult mice. Serum was obtained from single 
drops of blood collected from cheek veins at the time points indicated. 
Milk was taken from mice at days 2, 3 or 4 of lactation by gentle liquid aspiration from nipples 
with the plastic tubing (catheter) of a butterfly needle attached to a collection tube, itself 
connected to a cell culture vacuum pump (set at low suction power to enable sensitive 
aspiration). Lactating mice were treated by intraperitoneal injection of two units of oxytocin 
(03251-500U, Sigma-Aldrich) two minutes before milking.  
 
Fc-EDA was also administered intravenously to cynomolgus monkeys. A group of three male 
and three female monkeys and a second group of five males and five females were treated by 
twice weekly infusion of Fc-EDA at dose levels of 30 or 100 mg/kg/dose, respectively, for three 
weeks. An additional group of five animals of each sex which received the vehicle, 20 mM 
sodium phosphate, 300 mM sodium chloride, pH 7.2, and 0.02% Polysorbate 20 (w/v), served as 
control. The dose volume for all groups was 20 mL/kg/dose (10 mL/kg/hour). Following the 
treatment period, some animals were maintained for a 15-day recovery period. Observations 
regarding morbidity, mortality, injury, and the availability of food and water were conducted 
twice daily for all animals. Clinical observations took place twice weekly during the treatment 
period and weekly during recovery. Body weights were measured and recorded weekly. 
Ophthalmoscopic examinations were conducted before drug delivery and prior to each scheduled 
necropsy. Electrocardiography was done on day 15 and prior to post-recovery necropsy. Blood 
samples for determination of the serum concentrations of EDA were collected from all animals 
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on days 1 and 19 and prior to the post-recovery necropsy. The toxicokinetic parameters were 
determined for the drug from concentration-time data in the test species. Blood samples for 
evaluations of immunogenicity and blood and urine samples for further evaluations were 
obtained before drug delivery and prior to the necropsies. At the necropsies, examinations were 
performed, organ weights were recorded, and tissues were examined microscopically. 
To evaluate the potential placental transfer of the drug, five pregnant monkeys received Fc-EDA 
intravenously at doses of 10, 30, and 100 mg/kg body weight and were sacrificed one to 12 hours 
later. Observations of the animals included clinical signs, body weights, heart rate, respiration 
rate, and body temperature. A toxicokinetic assessment was made. 
 
Protein quantification by ELISA 
Fc-EDA in 100 µl of 133-fold diluted sera (and 2-fold dilutions thereof) was quantified using 
ELISA plates coated with 100 µl of hEDAR-mFc (1 µg/ml) per well and revealed with a 
peroxidase-coupled anti-human IgG antibody; mAbEDAR1 was quantified similarly on hEDAR-
hFc-coated plates and revealed with a peroxidase-coupled anti-mouse IgG antibody. Details of 
the ELISA procedure have been published.5 EC50 was determined using the “log(agonist) vs. 
normalized response – variable slope” function of Prism software. 
 
Prenatal treatment of human patients 
In three cases of male human fetuses with the prenatal diagnosis of XLHED (two monochorionic 
twins and a single fetus), written informed consent for prenatal intra-amniotic administration of 
Fc-EDA as an individual “Heilversuch” (trial to cure) was given by the parents and approval of 
the clinical ethics committee of the University Hospital Erlangen was obtained. At week 26 of 
gestation, some amniotic fluid was removed and Fc-EDA (EDI200, provided by Edimer 
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Pharmaceuticals Inc.; same batch as used in the clinical trial NCT01775462 on affected 
neonates; doses of 70 to 75 mg in a total volume of 14 to 15 mL sterile solution) was injected 
under ultrasound guidance into the amniotic cavity of each fetus. At gestational week 31, a 20-
mL sample of amniotic fluid was withdrawn and a second injection of 140 mg of Fc-EDA in a 
volume of 28 mL was performed in two cases.  
Fc-EDA concentrations in the serum of pregnant women, in amniotic fluid samples and in the 
serum of treated patients were determined by MPI Research Inc. (Mattawan, USA). 
 
Investigation of untreated affected siblings and other control subjects 
The older brother of the treated twins who also carries the EDA mutation Y304C was 
investigated in parallel to his siblings. He had suffered several hyperthermic episodes in early 
infancy and was enrolled in the natural history study ECP-015 (ClinicalTrials.gov 
NCT02099552). The older brother of the third treated patient carries the EDA mutation 
V309GfsX8. He had been referred to the University Hospital Erlangen because of his 
characteristic facial appearance and repeated occurrence of unexplained fever soon after birth 
and was also investigated in parallel to his sibling. Three more boys and one male adult with the 
EDA mutation Y304C who had been examined in previous studies6-8 or seen at the University 
Hospital Erlangen served as additional controls. Samples of healthy control subjects age-matched 
to the treated infants were investigated by confocal laser-scanning microscopy (n = 6) and 
quantification of pilocarpine-induced sweating (n = 6) at the University Hospital Erlangen. 
Unstimulated saliva flow was determined in the treated twins, their older brother and two healthy 
2-year-old infants. The adult provided written informed consent to participate in the study; in the 
case of minors, parental consent and if possible assent of the child were obtained. 
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Confocal laser-scanning microscopy  
Reflectance confocal laser-scanning microscopy of skin areas of 36 mm² to determine sweat pore 
densities was conducted with a VivaScope 1500 (Caliber Imaging & Diagnostics, New York, 
USA) according to the manufacturer’s instructions. The dermal ridges of the infants treated in 
utero were investigated in comparison with older siblings and healthy control infants. 
 
Quantification of pilocarpine-induced sweating 
Sweat was collected by a standardized procedure from an area of 57 mm² of the right or left 
forearm 30 min after stimulation with a pilocarpine gel disk using the Wescor 3700 device 
(Wescor, Logan, USA). Maximum volume that could be collected in this device was 93 µL. The 
volume was determined immediately after sampling. 
 
Quantification of saliva flow 
Whole saliva was collected with the Quantisal oral fluid collection device (Immunalysis, 
Pomona, USA) between 10:00 and 13:00 hours, after the subjects had refrained from eating and 
drinking for a period of 1 hour. All infants were instructed to swallow once before the test started 
and told to refrain from swallowing or talking during saliva collection for a total of 120 seconds. 
The pre-weighted fluid collector was positioned under the tongue, and the head of the subject 
was kept down to allow gravity to help with fluid collection. In none of the tests the volume limit 
indicator turned blue during the procedure. After the collection period, the weight increase of the 
collector was determined on a special accuracy weighing machine (Sartorius Lab Instruments, 
Göttingen, Germany), and the saliva flow rate was calculated in mL/min. Oral fluid collection 
was repeated three times at different days or with intervals of at least 40 minutes.   
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Dental imaging 
In the treated twins, magnetic resonance imaging (MRI) of the head was conducted at the age of 
two months. Dental radiography was done when the infants were 6 to 12 months old (age 
corrected for preterm birth). 
 
Data availability 
The datasets generated and/or analyzed during the current study are either included in this article 
(and its Supplementary appendix) or available from a data depository 
(DOI: 10.5281/zenodo.1164154), or will be provided by the corresponding author on reasonable 
request.  
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SUPPLEMENTARY FIGURES 
 
 
 
 
Figure S1. EDA mutation Y304C grossly affects solubility of the protein.  
a, Position of tyrosine 304 (Y304) in the crystal structure of the C-terminal TNF-homology 
domain of EDA (pdb accession number 1RJ7) in a top view of the homotrimeric protein. Y304 is 
situated at the interface of adjacent protomers in the crystal structure.  
b, same as panel a, but viewed from the side. In this representation, the receptor-expressing cell 
would be at the bottom of the picture. 
c, Flag-EDA1-WT (wild-type) and Flag-EDA1-Y304C were expressed as recombinant proteins 
in 293T cells and detected in cell extracts and conditioned culture medium by Western blot using 
the anti-EDA monoclonal antibody Renzo-2. Although Flag-EDA1-Y304C is expressed, none 
was found to be secreted. The black and white arrowheads point at the non- and mono-N-
glycosylated forms of Flag-EDA1, respectively.9 
d, Coomassie blue staining of cell extracts used in panel c to document comparable loading.  
The experiment in panels c and d was performed twice with similar results. 
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Figure S2. Phenotypic reversion of 
EDA-deficient mice depends on the 
neonatal Fc receptor. 
a, Representative pictures of tails and 
paws of EDA-deficient mice treated in 
utero (E14.5) by intra-amniotic 
administration of ACRP-EDA (EDA 
without Fc) or Fc-EDA. Sweat gland 
function was visualized by starch-
iodine staining (dark dots with a 
characteristic pattern).  
b, Intra-amniotic administration of Fc-
EDA to EDA-deficient mouse fetuses, 
some of which were devoid of the 
neonatal Fc receptor, resulted in 
phenotypic reversion (darker coat with 
plenty of guard hair, a hairy tail, 
functional sweat glands, larger and 
more complex molars) only of those 
animals expressing the neonatal Fc 
receptor. Scale bar: 500 µm. 
 
Photographs of 232 further mice used 
in this study are shown in Extended 
Figure S1 accessible under the DOI: 
10.5281/zenodo.1164154. 
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Figure S3. Detection of EDAR agonists in milk after intraperitoneal administration. 
EDAR agonists (10 mg/kg) were administrated intraperitoneally to dams after delivery (at days 
1, 2 or 3 of lactation) and milk was collected 24 h later.  
a, Standard curve of mAbEDAR1 binding to hEDAR-hFc by ELISA. 
b, Detection of mAbEDAR1 in milk of neonatal Fc receptor (FcRn)-deficient dams by its ability 
to bind to hEDAR-hFc by ELISA.  
c, Standard curve of Fc-EDA binding to hEDAR-mFc by ELISA. 
d, Detection of Fc-EDA in milk of FcRn-deficient dams by its ability to bind to hEDAR-mFc by 
ELISA.  
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Figure S4. Efficacy of EDAR agonists to correct tail hair and sweat glands in EDA-
deficient mice in the presence or absence of neonatal Fc receptor (FcRn). 
Mice of the indicated genotypes were treated at birth with the indicated doses of mAbEDAR1 or 
Fc-EDA. Tail hair and sweating ability were scored three weeks later. Fcgrt is the gene encoding 
FcRn. After exclusion of the results indicated in brackets, the average reversion score for each 
treatment dose was used to determine EC50. The curve was manually superimposed on graphs.  
a, mAbEDAR1 in pups heterozygous for FcRn.  
b, mAbEDAR1 in FcRn-deficient pups.  
c, Fc-EDA in pups wild-type for FcRn. 
d, Fc-EDA in pups heterozygous for FcRn. 
e, Fc-EDA in FcRn-deficient pups.  
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Figure S5. Determination of the half-life of Fc-EDA in FcRn-deficient adult mice. 
FcRn-deficient or heterozygous mice were treated by intravenous injection of 200 µg of Fc-
EDA. Small blood volumes were collected at the indicated time points for serum preparation and 
Fc-EDA was detected by ELISA as described in the legend to Fig. S2.  
a, Detection of Fc-EDA at the indicated concentrations. The figure shows average values ± SEM 
of three normalized standard curves. 
b, Detection of Fc-EDA in serum samples at the indicated time points after intravenous 
administration to mice lacking both EDA and FcRn. Data shown are from one mouse out of three 
with similar results.  
c, Fc-EDA concentration in sera was determined assuming that the concentrations at EC50 of 
curves in panel b are equal to the concentrations of pure Fc-EDA at EC50 in panel a. Results 
from three mice are shown (white, grey and black circles). The half-life of Fc-EDA was 
estimated as indicated. For time points where EC50 could not be determined (1 h and 2 h), Fc-
EDA concentrations were measured by direct comparison with the standard curve of panel a. The 
dotted line indicates the distribution phase and the solid line the elimination phase, from which 
the half-life of Fc-EDA was estimated. 
d, same as panel a, but showing the average ± SEM of two standard curves.  
e, same as panel b, but in an EDA-deficient mouse heterozygous for FcRn.  
f, same as panel c, but in EDA-deficient mice heterozygous for FcRn.   
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             a 
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Figure S6. Efficient unstimulated sweating and salivation of the twins treated in utero. 
Male twins with the EDA mutation Y304C who had both received prenatal Fc-EDA treatment 
were investigated repeatedly after birth. 
a, Wet baby car seat of one of the treated twins in the summer documenting unstimulated 
sweating (spillage of urine or other liquids could be excluded). 
b, Assessment of salivation at the age of 21 months (together with the untreated affected 
brother). Saliva collected over a period of 120 seconds was quantified gravimetrically. All 
samples were obtained between 10:00 and 13:00 hours, after the subjects had refrained from 
eating and drinking for a period of 1 hour. Each column shows the average of three independent 
measurements, error bars indicate the standard deviation.  
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SUPPLEMENTARY TABLES  
 
Table S1. Phenotypic correction of individual EDA-deficient (Tabby) mice following treatment with EDAR agonists. 
 
  Administration Genotype of dam Genotype of the pups  Guard Ear Tail Sweat  
Drug Dose Time Route Eda Fcgrt Eda Fcgrt Teeth hair hair hair ducts Remarks 
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 2   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 3 3 3 3 3   
Fc-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3   
              
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 1 0 0 0  
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ n.d. 0 0 0 n.d.   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 2 2 3 1 * 
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 1 1 0 0 * 
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ 0 0 0 0 0   
ACRP-EDA 35 µg E14.5 i.a. Tabby +/+ Tabby +/+ n.d. 0 0 0 n.d.   
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ACRP-EDA 4 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 2.5 3   
ACRP-EDA 4 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 3 3  
ACRP-EDA 4 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 2.5 2  
 
ACRP-EDA 1 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 1 3  
ACRP-EDA 1 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 2 3  
ACRP-EDA 1 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 3 2  
ACRP-EDA 1 mg/kg P1 i.p. Tabby +/+ Tabby +/+ n.d. n.d. n.d. 3 3  
 
Fc-EDA 58 µg E13.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3  
Fc-EDA 58 µg E13.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3  
Fc-EDA 58 µg E13.5 i.a. Tabby +/+ Tabby +/+ 2 3 3 3 3  
 
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 1 3 0 0 0.5 * 
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 1 0 0 0  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby -/- n.d. 0 0 0 0   
              
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby +/- 1.5 3 3 3 3   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby +/- 2 3 3 3 1.5   
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby +/- 2 3 3 2 1.5  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby +/- 2 3 3 1.5 0  
Fc-EDA 58 µg E13.5 i.a. Tabby -/- Tabby +/- 1.5 3 3 1.5 1  
 
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby -/- 0 1 0 0 0   
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby -/- 0 0 0 0 0   
              
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby +/- 2 3 3 1 0.5   
Fc-EDA 58 µg E12.5 i.a. Tabby -/- Tabby +/- 0.5 3 3 0.5 0   
Prenatal Correction of XLHED           Schneider et al.      Suppl. Page   
 
 
17 
 
E preceding a number indicates an embryonic day, and P denotes a postnatal day. Treatment after birth does not rescue the 
development of teeth, guard hair, or ear hair; therefore, these scores were not determined for mice that were treated after birth. 
              
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 1 0.5   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 1 1.5   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0.5 0   
              
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 1 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 3   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 2.5   
mAbEDAR1 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 3 2.5   
              
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby -/- n.d. n.d. n.d. 0 0   
              
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 1 2   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 0 0   
Fc-EDA 10 mg/kg P1-P3 i.p., dam Tabby -/- Tabby +/- n.d. n.d. n.d. 1 2   
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Teeth score (excluding the third molar): 0 = narrow molars, shallow cusps, no or rudimentary anterior cusp on molar number 1 (M1); 
1 = wider molars, more defined cusps, one small anterior cusp on M1; 2 = wide molars, well-defined cusps, stubby anterior cusp on 
M1; 3 = like 2, but elongated anterior cusp on M1 (making ~1/3 of the length). Guard hair score (evaluated on a photography of the 
back of the mouse): 0 = no guard hair; 1 = between one and five guard hairs visible; 2 = sparse guard hair; 3 = numerous guard hairs 
all over the picture. Ear hair (skin area at the rear side of the ears evaluated): 0 = no hair, naked skin; 1 = very few hairs; 2 = sparse 
hair; 3 = dense hair, skin covered. Tail hair: 0 = none; 1 = sparse and only on one side of the tail; 2 = hair on both sides of the tail, 
usually dense on one side and sparse on the other; 3 = dense hair on both sides of the tail. Sweat ducts (evaluated on a photography of 
the paw showing all six foot pads after starch-iodine staining): 0 = no sweat spot; 1 = few spots on at least one foot pad; 2 = several 
spots on three or more foot pads; 3 = numerous sweat spots on at least five foot pads. 
i.a., intra-amniotic; i.p., intraperitoneal; n.d., not determined; *, partial reversion observed in these animals might have been due to 
accidental damage of the foetus or a yolk sac vessel during the injection procedure. 
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Table S2. EDA serum concentrations after intravenous infusion administration of Fc-EDA to pregnant monkeys.   
 
 
NA, not applicable. Standard deviation (SD) and coefficient of variation (CV) are not reported, when mean concentration equals zero 
or n<3.   
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Table S3. Adverse events observed in the three human case studies.  
 
Subject(s) 
affected 
Event Grade Treatment Outcome Causality assessment 
(WHO-UMC system) 
mother of 
patients 1 and 2 
(twins) 
premature 
contractions with 
cervical dilation 
severe tocolytic treatment (nifedipine, partusistene, 
atosiban) for one day, then caesarean section 
in a hospital close to subject’s home 
resolved possibly related to 
prenatal treatment 
patients 1 and 2 preterm birth severe standard treatment on a neonatal unit close 
to patients’ home for 6 weeks 
without 
sequelae 
possibly related to 
prenatal treatment 
patient 2 
(15 months old) 
allergic reaction 
to egg proteins 
severe medication (prednisolone suppository, 
Fenistil drops), hospitalization for one night 
resolved unlikely to be related 
to prenatal treatment 
mother of 
patients 1 and 2 
atopic dermatitis 
(since infancy) 
mild topical treatment as needed unresolved not related to prenatal 
treatment 
patient 2 
(8 months old) 
atopic dermatitis moderate topical treatment as needed unresolved unlikely to be related 
to prenatal treatment 
patient 1 
(8 months old) 
atopic dermatitis mild topical treatment as needed unresolved unlikely to be related 
to prenatal treatment 
patient 1 
(19 months old) 
increased serum 
urea level 
mild none resolved unlikely to be related 
to prenatal treatment 
patient 2 
(19 months old) 
increased serum 
urea level 
mild none resolved unlikely to be related 
to prenatal treatment 
patient 2 
(19 months old) 
thrombocytosis mild none resolved unlikely to be related 
to prenatal treatment 
mother of 
patients 1 and 2 
thrombocytosis 
(recently)   
mild none resolved unlikely to be related 
to prenatal treatment 
mother of 
patients 1 and 2 
vitamin D 
deficiency 
mild vitamin D supplementation as needed unknown not related to prenatal 
treatment 
mother of 
patient 3 
elective caesarean 
section 
NA standard obstetric treatment in a hospital 
close to subject’s home 
resolved not related to prenatal 
treatment 
patient 3  
(4 months old) 
Urticaria 
pigmentosa 
moderate cetirizine drops for two weeks, since then 
only rarely administered as needed 
nearly 
resolved 
unlikely to be related 
to prenatal treatment 
patient 3 
(10 months old) 
Hand-Foot-Mouth 
disease 
moderate symptomatic treatment resolved not related to prenatal 
treatment   
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Table S4. Plasmids used for the experiments.  
 
Plasmid Designation (gene product) Protein encoded Vector 
ps015 Empty vector None PCR3 
ps869 ACRP-EDA Signal-Flag-GPGQVQLH-mACRP30 (aa 18-111)-LQ-mEDA1 (aa 245-391) PCR3 
ps930 hEDAR-hFc hEDAR (aa 1-183)-VD-hFc (aa 224-449 of UniProt entry P0DOX5) PCR3 
ps1938 Fc-EDA1 (EDI200) Signal-hFc (aa 224-449)-hEDA1 (aa 238-391) PCR3 
ps2270 hEDAR-mFc hEDAR (aa 1-183)-mFc (aa 237-463 of UniProt entry U5LP42) pEF1 
ps3423 Flag-EDA Signal-Flag-GPGQVQLQVD-mEDA1 (aa 245-391) PCR3 
ps3754 Flag-EDA Y304C Signal-Flag-GPGQVQLQVD-mEDA1 (aa 245-391) Y304C PCR3 
 
Flag = DYKDDDDK      HA signal=MAIIYLILLFTAVRG       mEDA1 and hEDA1 are 100% identical in amino acids 245-391 
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